Current Opinion in Oncology

Papers
(The TQCC of Current Opinion in Oncology is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-02-01 to 2024-02-01.)
ArticleCitations
Epidemiology of head and neck cancers: an update151
Lung cancer in China: current and prospect123
Molecular alterations in meningioma: prognostic and therapeutic perspectives51
Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting49
Advances in immunotherapy for cervical cancer45
The microenvironment in myeloma42
Update on oncogenesis and therapy for Kaposi sarcoma37
Models of supportive care in oncology35
Computational analysis of flow cytometry data in hematological malignancies: future clinical practice?31
Viral strategies for circumventing p53: the case of severe acute respiratory syndrome coronavirus31
Use of noninvasive imaging in the management of skin cancer31
Malignant pleural mesothelioma: recent developments26
Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma24
BRAF mutations in thyroid cancer24
Antibody–drug conjugates in breast cancer: the chemotherapy of the future?23
CD19-directed CAR T-cell therapy in B-cell NHL23
Current concepts in the treatment of giant cell tumour of bone22
Recent progress in treating advanced prostate cancer21
Targeting HER2 heterogeneity in early-stage breast cancer20
Single-cell and spatial transcriptomics approaches of the bone marrow microenvironment18
Multimodality treatment for localized gastric cancer: state of the art and new insights17
Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives17
Filling the gaps of patient information and comprehension17
Current emerging MRI tools for radionecrosis and pseudoprogression diagnosis16
The roaring 2020s: a new decade of systemic therapy for renal cell carcinoma16
Sinonasal cancers treatments: state of the art16
Molecular prediction of metastasis in cutaneous squamous cell carcinoma16
Geriatric assessments and frailty scores in multiple myeloma patients: a needed tool for individualized treatment?15
MEK inhibitors in RASopathies15
Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer15
Targeting SUMOylation in cancer15
Cabozantinib as an emerging treatment for sarcoma14
New drugs in gastrointestinal stromal tumors14
Clinical data, limitations and perspectives on chimeric antigen receptor T-cell therapy in multiple myeloma14
Single-cell sequencing in hematology14
Retroperitoneal sarcoma: the Transatlantic Australasian Retroperitoneal Sarcoma Working Group Program13
Adjuvant therapy of operable nonsmall cell lung cancer: an update13
Adrenocortical carcinoma: current treatment options13
Updated concepts in treatment of giant cell tumor of bone13
Triplet combination of BRAF, MEK and PD-1/PD-L1 blockade in melanoma: the more the better?13
The role of the tumor matrix environment in progression of head and neck cancer13
The emerging data on choice of optimal therapy for locally advanced nasopharyngeal carcinoma12
Targeted radionuclide therapy: an emerging field in solid tumours12
Adjuvant chemotherapy in rectal cancer: state of the art and future perspectives12
The evolving treatment paradigm of advanced hepatocellular carcinoma: putting all the pieces back together12
New targets and technologies for CAR-T cells12
Mechanisms of invasion in glioblastoma12
Progress in the management of endometrial cancer (subtypes, immunotherapy, alterations in PIK3CA pathway): data and perspectives12
T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities12
Next-generation sequencing for the management of sarcomas with no known driver mutations12
Opportunities and challenges associated with the evaluation of chimeric antigen receptor T cells in real-life12
The role of myeloid-derived suppressor cells in hematologic malignancies11
Therapeutic targeting of the DNA damage response in prostate cancer11
EGFR-mutant NSCLC: emerging novel drugs11
Immunotherapy and breast cancer: an overview11
Challenges and opportunities in the management of metastatic renal cell carcinoma: combination therapy and the role of cytoreductive surgery11
Dissecting the spatial bone marrow microenvironment of hematopoietic stem cells11
Immunobiology of Merkel cell carcinoma10
Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?10
Harnessing dendritic cells for innovative therapeutic cancer vaccines10
Lifestyle and quality of life in patients with early-stage breast cancer receiving adjuvant endocrine therapy10
Tropomyosin receptor kinase inhibitors in the management of sarcomas9
Systemic treatment of metastatic squamous cell carcinoma of the head and neck: proposal for management changes9
Management of epilepsy in brain tumor patients9
Integrating new oral selective oestrogen receptor degraders in the breast cancer treatment9
New perspectives on targeting RAF, MEK and ERK in melanoma9
Novel therapeutic options for alveolar soft part sarcoma: antiangiogenic therapy, immunotherapy and beyond9
Adjuvant chemotherapy in colon cancer: state of the art and future perspectives9
131I-metaiodobenzylguanidine and peptide receptor radionuclide therapy in pheochromocytoma and paraganglioma9
Indications of next-generation sequencing in non-Hodgkin's lymphoma9
Bromodomain and extraterminal domain protein bromodomain inhibitor based cancer therapeutics9
Targeting BRAF and MEK inhibitors in melanoma in the metastatic, neoadjuvant and adjuvant setting8
Primary vitreoretinal lymphoma: short review of the literature, results of a European survey and French guidelines of the LOC network for diagnosis, treatment and follow-up8
Combining immunotherapy and radiotherapy in head and neck squamous cell cancers: which perspectives?8
Immunomodulation for hepatocellular carcinoma therapy: current challenges8
Interventions addressing fear of cancer recurrence: challenges and future perspectives8
Treatment updates on tenosynovial giant cell tumor8
An update on adult forms of hereditary pheochromocytomas and paragangliomas8
Mitogen-activating protein kinase pathway alterations in Langerhans cell histiocytosis8
Immune escape mechanisms in head and neck squamous cell carcinoma and implication for new immunotherapy approach8
Recent advances in primary resistance mechanisms against immune checkpoint inhibitors8
Preoperative immunotherapy for head and neck cancers: state of art8
Overcoming key challenges in cancer immunotherapy with engineered T cells8
Beyond ibrutinib: novel BTK inhibitors for the treatment of chronic lymphocytic leukemia7
New molecular entities of soft tissue and bone tumors7
Targeting microRNA in hematologic malignancies7
Role of metabolic imaging in diagnosis of primary, metastatic, and recurrent prostate cancer7
Epigenetic focus on angioimmunoblastic T-cell lymphoma: pathogenesis and treatment7
COVID-19 and supportive cancer care: key issues and opportunities7
Medical treatment of advanced malignant perivascular epithelioid cell tumors7
Adjuvant chemotherapy in biliary tract cancer: state of the art and future perspectives7
Image-guided surgery in oral cancer: toward improved margin control7
Lung cancer screening: a critical appraisal7
Current status of phosphoinotiside-3 kinase inhibitors in blood cancers7
Novel immunotherapeutic drugs for the treatment of lung cancer6
Targeting the methionine−methionine adenosyl transferase 2A−S-adenosyl methionine axis for cancer therapy6
Mechanisms of resistance and predictive biomarkers of response to targeted therapies and immunotherapies in metastatic melanoma6
Bacterial infection-driven lymphomagenesis6
Tyrosine kinase inhibitors as induction therapy in nonsmall-cell lung cancer6
Supportive care for new cancer therapies6
HIPEC in advanced epithelial ovarian cancer: why is there controversy?6
The road to chemotherapy-free treatment in chronic lymphocytic leukaemia6
Cost-effectiveness of newer regimens for the prophylaxis of chemotherapy-induced nausea and vomiting: review of the literature and real-world data6
Anaplastic thyroid carcinoma: advances in molecular profiling and targeted therapy6
Is less more in the surgical treatment of early-stage cervical cancer?6
0.047128915786743